Edwards Lifesciences Securities Settlement (2026)

Status: Live (claims open)

Summary & Commentary

Edwards Lifesciences is a leading maker of transcatheter aortic valve replacement (TAVR) devices, its core business. Investors sued the company and CEO Bernard J. Zovighian, claiming that between February and July 2024 they made false and misleading statements about how fast the TAVR business would grow, which kept the stock price artificially high until the truth came out.

The claims were brought under Sections 10(b), 20(a) and 20A of the Securities Exchange Act and SEC Rule 10b-5. After a partly successful motion to dismiss, discovery and mediation, the parties agreed to a $39 million settlement. Edwards denies wrongdoing. Investors who file with trade records share the net fund.

---

TL;DR

• Who: People and entities that bought or acquired Edwards common stock during the class period and were damaged
• When: February 6, 2024 – July 24, 2024 (inclusive)
• Benefit: Pro rata share of a $39,000,000 fund
• Deadline: December 2, 2026
• Proof required: Yes, trade confirmations or brokerage statements
• Administrator: Kroll Settlement Administration

---

Who Is Included

All persons or entities that purchased or otherwise acquired Edwards common stock from February 6, 2024 through July 24, 2024, inclusive, and were damaged.

Excluded are the defendants, their successors and assigns, past and current executive officers and directors, immediate family members of Mr. Zovighian and the former individual defendants, entities they control, their legal representatives and heirs, and anyone who opts out.

What You Could Receive

A pro rata share of the net fund after attorneys' fees, litigation expenses, taxes and administration costs, calculated under the court-approved Plan of Allocation. No per-share or per-person amount has been set. Only claimants with valid, documented claims are paid.

Key Dates

• Opt-out deadline: December 2, 2026
• Objection deadline: December 2, 2026
• Claim deadline: December 2, 2026
• Final approval hearing: December 16, 2026

What You Need To Do

1. Gather trade confirmations or monthly statements for your Edwards purchases, acquisitions and sales during the class period.
2. File online through the claim portal, or mail the claim form to Kroll Settlement Administration, P.O. Box 5014, New York, NY 10150-5014.
3. Submit by December 2, 2026.

Frequently Asked Questions

What is TAVR? Transcatheter aortic valve replacement, a minimally invasive heart valve procedure and Edwards' main product line.

How much will I get? It depends on your losses and the total valid claims.

What if I do not file? You receive nothing.

What This Case Is About

The plaintiffs alleged Edwards and its CEO made materially false and misleading statements about the growth prospects of the TAVR platform, inflating the stock price, in violation of federal securities laws. The defendants deny all allegations and say they acted in good faith. The settlement followed a mediator's recommendation.

Administrator

Kroll Settlement Administration

• Mail: P.O. Box 5014, New York, NY 10150-5014
• Phone: 1-833-930-0555
• Email: info@EdwardsLifesciencesSecuritiesLitigation.com
• Website: edwardslifesciencessecuritieslitigation.com

Important Documents

The Notice of Pendency and Proposed Settlement, Claim Form, Stipulation of Settlement, court orders and the Plan of Allocation (Appendix A to the Notice) are available on the settlement website.